Mitiglinide Calcium Dihydrate

Summary

Mitiglinide Calcium Dihydrate (CHEMBL4298005) is a phase-3 clinical-stage unknown; indicated across 1 condition including type 2 diabetes mellitus.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 1 condition
• Clinical trials: 3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4298005
Name	Mitiglinide Calcium Dihydrate
Type	Unknown
Max phase	3

Also known as: Glufast, Kad-1229, KAD-1229, Mitiglinide calcium dihydrate, Mitiglinide calcium hydrate, Mitiglinide calcium salt dihydrate, S-21403, MITIGLINIDE CALCIUM DIHYDRATE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
type 2 diabetes mellitus	3	MONDO:0005148	MONDO:0005148

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE4	1
PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02154347	PHASE4	COMPLETED	Post-marketing Clinical Trial of KAD-1229 in Patients With Type 2 Diabetes Mellitus
NCT01333592	PHASE3	COMPLETED	Long-term Study of KAD-1229 in Type 2 Diabetes Patients
NCT01403818	PHASE1	COMPLETED	A Study to Assess the Effect of ASP1941 and Mitiglinide on Their Plasma Concentration

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).